Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blinded, Placebo-Controlled Phase I Study to Evaluate the Safety and Efficacy of Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blinded, Placebo-Controlled Phase I Study to Evaluate the Safety and Efficacy of Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DMI 9523 (Primary)
  • Indications Adult respiratory distress syndrome; Post acute COVID 19 syndrome
  • Focus Adverse reactions
  • Acronyms Long COVID
  • Sponsors Ampio Pharmaceuticals

    • Most Recent Events

    • 16 May 2022 Status changed from active, no longer recruiting to completed.
    • 29 Mar 2022 According to an Ampio Pharmaceuticals media release, Enrollment was completed in December 2021, and the Day 60 post-treatment safety and efficacy measures are currently underway.
    • 29 Mar 2022 According to an Ampio Pharmaceuticals media release, is on track to complete the data analysis by the end of the second quarter of 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top